Bicycle therapeutics announces publication of article highlighting preclinical data from bt8009 program in molecular cancer therapeutics

Cambridge, england, & boston--(business wire)--bicycle therapeutics plc (nasdaq:bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that an article highlighting preclinical data from bt8009, a nectin-4 targeting bicycle toxin conjugate, was published in molecular cancer therapeutics. the article, titled “bt8009: a nectin-4 targeting bicycle® toxin conjugate for treatment of soli
BCYC Ratings Summary
BCYC Quant Ranking